Atossa Therapeutics, Inc. (ATOS)
| Market Cap | 159.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.96M |
| Shares Out | 10.16M |
| EPS (ttm) | -1.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $2.23 |
| Previous Close | $2.14 |
| Change ($) | 0.09 |
| Change (%) | 4.21% |
| Day's Open | 2.19 |
| Day's Range | 1.78 - 2.34 |
| Day's Volume | 12,578,250 |
| 52-Week Range | 0.76 - 5.08 |
It's fine to own ATOS stock based on the Covid-19 angle, but a broader view of the company reveals a commitment to under-treated conditions. The post Atossa Therapeutics Has a Covid-19 Connect...
Atossa Therapeutics Inc (NASDAQ: ATOS) announces final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients rece...
SEATTLE, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Investors are excited about the potential of the biotech's experimental breast cancer treatment.
Atossa Therapeutics (ATOS) stock is on the rise with heavy trading Thursday after announcing some positive breast cancer news. The post ATOS Stock: 8 Things for Investors to Know About Atossa ...
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...
SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...
SEATTLE, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...
SEATTLE, Jan. 29, 2021 /PRNewswire/ -- A paper was published today by Dr. Steven Quay, M.D., PhD., CEO of Atossa Therapeutics, Inc. (NASDAQ: ATOS), entitled, "A Bayesian analysis concludes bey...
SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...
HOUSTON, Jan. 8, 2021 /PRNewswire/ -- Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS ), recently shared his latest research a...
SEATTLE, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop inno...
SEATTLE, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (the “Company” or “Atossa”), a clinical-stage biopharmaceutical company seeking to discover and develop inno...
SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
SEATTLE, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
SEATTLE, Oct. 28, 2020 /PRNewswire/ -- A paper published on Zenodo (DOI 10.5281/zenodo.4119263) by Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics...
SEATTLE, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
In honor of October Breast Cancer Awareness Month, Atossa’s CEO Dr. Steven Quay, M.D., Ph.D. & CFO Kyle Guse will deliver a presentation titled “Atossa Therapeutics: Tackling our Greatest Heal...
SEATTLE, Oct. 2, 2020 /PRNewswire/ -- Renowned physician-scientist Dr. Steven Quay, MD, PhD, and CEO of Atossa Therapeutics, Inc. (NASDAQ: ATOS) has provided 50 copies of his best-selling book...
SEATTLE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas...
Safety Committee Allows Enrollment in First 14-Day, Multi-Dose Study Arm Safety Committee Allows Enrollment in First 14-Day, Multi-Dose Study Arm
SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas...
Volatility can be your best friend if you trade based on chart patterns. These penny stocks could be profitable in tumultuous times.
SEATTLE, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...
SEATTLE, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...
SEATTLE, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...
Enrollment Expected to Begin Within 30 days Enrollment Expected to Begin Within 30 days
Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrence Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer...
Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., will address recent progress with two COVID-19 treatment programs Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., will address recent progress with two ...
SEATTLE, July 16, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...
Results Support Development of Proprietary AT-301 Nasal Spray for COVID-19 Patients Results Support Development of Proprietary AT-301 Nasal Spray for COVID-19 Patients
SEATTLE, July 08, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...
SEATTLE, June 11, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas ...
Atossa Therapeutics: Feeling Bullish About COVID-19 Program
AT-301 Intended to Prevent COVID-19 and Treat Early Cases Via Nasal Delivery AT-301 Intended to Prevent COVID-19 and Treat Early Cases Via Nasal Delivery
Atossa Therapeutics (NASDAQ: ATOS) shares are trading higher on Wednesday. The company announced "successful" in vitro testing results of AT-H201, which is Atossa's proprietary COVID-19 drug c...
Results Support Development of AT-H201 for COVID-19 Patients Results Support Development of AT-H201 for COVID-19 Patients
SEATTLE, May 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas o...
SEATTLE, May 07, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in area...
Atossa Therapeutics Inc. (NASDAQ: ATOS) is the newest company to join the fight against COVID-19.
Combination of two drugs previously approved by the FDA for other diseases to be developed to reduce patient time on a ventilator Combination of two drugs previously approved by the FDA for ot...
Company’s Clinical Development Has Not Been Impacted by COVID-19 Company’s Clinical Development Has Not Been Impacted by COVID-19
Speculative Spotlight: Atossa Therapeutics Offers An Enticing Risk-Reward
SEATTLE, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS) today issued the following letter from Dr. Steven C. Quay, President and CEO, to Atossa shareholders:
SEATTLE, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast ca...
SEATTLE, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast ca...
Susan Love, M.D., inventor of the technology, will advise Atossa on the study Susan Love, M.D., inventor of the technology, will advise Atossa on the study
All Objectives Successfully Met – Phase 2 Study to Start Q4 2019 All Objectives Successfully Met – Phase 2 Study to Start Q4 2019
SEATTLE, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast c...
About ATOS
Atossa Therapeutics develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was f... [Read more...]
| Industry Biotechnology | IPO Date Nov 8, 2012 |
| CEO Steven Quay | Employees 4 |
| Stock Exchange NASDAQ | Ticker Symbol ATOS |
Analyst Forecasts
According to 2 analysts, the average rating for ATOS stock is "Buy." The 12-month stock price forecast is 6.25, which is an increase of 180.27% from the latest price.